Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spark Therapeutics Inc.

Division of Roche
www.sparktx.com

Latest From Spark Therapeutics Inc.

A Positive Outlook For Deals, With Election Year Caveats

Industry advisers at the BIO CEO & Investor meeting remained optimistic about the pharmaceutical deal environment in 2020 – even with the uncertainty around a looming US election year. 

Deals Market Intelligence

Freeline Bags Alnylam's Heggie As CEO

Syncona-backed Freeline has nabbed an "accomplished commercial leader" in Theresa Heggie to lead the company as it prepares to take FLT180a, its gene therapy for hemophilia B, into Phase III.

Blood & Coagulation Disorders Gene Therapy

2019’s Top Biopharma Deal-Makers

Gene therapy and targeted oncology treatments dominated the biggest acquisitions of the year. Boehringer Ingelheim and Roche were the most active big pharma in-licensers. Cancer and neurology were the focus of most alliances and financings.

Deals Market Intelligence

Roche Partnering Casts Wide Net To Expand Company’s Neuroscience Pipeline

Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.

Deals Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Hepatic (Liver)
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Spark Therapeutics LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • Jeffrey D Marrazzo, CEO
    Stephen Webster, CFO
    Katherine A High, MD, Pres. & Head, R&D
    Daniel R Faga, CBO
    Frederico Mingozzi, PhD, CSO
  • Contact Info
  • Spark Therapeutics Inc.
    Phone: (215) 220-9300
    3737 Market St.
    Philadelphia, PA 19104
    USA
UsernamePublicRestriction

Register